Overview

Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults

Status:
Terminated
Trial end date:
2017-06-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether the combination of BMS-955176 with atazanavir (ATV) [with or without ritonavir (RTV)] and dolutegravir (DTG) is efficacious, safe, and well-tolerated in HIV-1 infected treatment experienced adults.
Phase:
Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
ViiV Healthcare
Collaborator:
GlaxoSmithKline
Treatments:
Atazanavir Sulfate
BMS-955176
Dolutegravir
Ritonavir
Tenofovir